Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3038% below fair value

$0.53−0.01 (-2.41%)

Close on Nov 13, 2026Market cap $81.19MP/E –Yield –

Coherus Oncology EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Coherus Oncology's EV/EBITDA was 3.3× on Apr 30, 2021, against 8.9× a year earlier.

Period	Period end	Value	Change (pts)
2021	Apr 30, 2021	3.3×	−1.5
2020	Dec 31, 2020	4.8×	−226.3
2019	Dec 31, 2019	231.1×	–

Parsed from the XBRL in Coherus Oncology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CHRS.

Revenue growth44.4% · median -54.0%

Operating margin-275.9% · median -222.6%

Net margin-253.4% · median -223.6%

Advertisement
300 × 250

See a number that looks wrong?